CCRN241018P15000
- 2.45
- 0.000.00%
Cross Country Healthcare Newsroom
Barrington Maintains Cross Country Healthcare(CCRN.US) With Buy Rating, Maintains Target Price $19
Cross Country Healthcare Analyst Ratings
Barrington Research Maintains Outperform on Cross Country Healthcare, Lowers Price Target to $19
Buy Rating Affirmed for Cross Country Healthcare Amidst Resilient Q2 Performance and Strategic Growth Potential
Cross Country Healthcare Analyst Ratings
Benchmark Co. Maintains Cross Country Healthcare(CCRN.US) With Buy Rating, Maintains Target Price $19
Oppenheimer Maintains Cross Country Healthcare(CCRN.US) With Hold Rating
Cross Country Healthcare (CCRN) Receives a Rating Update From a Top Analyst
JMP Securities Sticks to Its Hold Rating for Cross Country Healthcare (CCRN)
JMP Securities Maintains Cross Country Healthcare(CCRN.US) With Hold Rating
Barrington Research: Maintaining the Cross Country Healthcare (CCRN.US) rating, adjusted from better than market to better than market rating, and adjusted target price from $24.00 to $21.00.
Cross Country Healthcare Analyst Ratings
Barrington Research Maintains Outperform on Cross Country Healthcare, Lowers Price Target to $21
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cross Country Healthcare (CCRN), Castle Biosciences (CSTL) and Andlauer Healthcare Group (OtherANDHF)
Barrington Cuts Price Target on Cross Country Healthcare to $21 From $24, Maintains Outperform Rating
Benchmark: Maintain Cross Country Healthcare's (CCRN.US) rating, adjusted from buy to buy rating, and adjusted target price from $21.00 to $19.00.
Cross Country Healthcare Analyst Ratings
Benchmark Maintains Buy on Cross Country Healthcare, Lowers Price Target to $19
Analysts Offer Insights on Healthcare Companies: Cross Country Healthcare (CCRN) and Bio-Techne (TECH)
JMP Securities Sticks to Its Hold Rating for Cross Country Healthcare (CCRN)